The Application and Implications of Novel Deterministic Sensitivity Analysis Methods.

abstract：:We review regulation of two important parameters for third-party payers and manufacturers of prescription drugs: regulation of reimbursement and pricing. We find that centralised regulation of reimbursement and pricing prevails in the 15 original EU member countries (EU-15) and in European Free Trade Association (EFTA...

journal_title：PharmacoEconomics

authors： Gress S,Niebuhr D,May U,Wasem J

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Lung cancer is among the top causes of cancer-related deaths. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors can increase progression-free survival compared with standard chemotherapy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). OBJECTIVE:The aim o...

journal_title：PharmacoEconomics

authors： Schremser K,Rogowski WH,Adler-Reichel S,Tufman AL,Huber RM,Stollenwerk B

更新日期：2015-11-01 00:00:00

abstract：:The broad spectrum of antibacterial activity and favourable pharmacokinetic profile of ciprofloxacin permit oral treatment of many serious infections which have traditionally necessitated parenteral antibacterial therapy. This has been demonstrated in comparative studies, in which ciprofloxacin was as effective and w...

journal_title：PharmacoEconomics

authors： Balfour JA,Faulds D

更新日期：1993-05-01 00:00:00

abstract：:Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article. ...

journal_title：PharmacoEconomics

authors： Wehler E,Boytsov N,Nicolay C,Herrera-Restrepo O,Kowal S

更新日期：2020-01-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic, generally progressive autoimmune disease that causes functional disability, significant pain and joint destruction, and leads to premature mortality. It is estimated to affect between 0.5 and 1.0% of the adult population worldwide, increases in prevalence with age and affects mo...

journal_title：PharmacoEconomics

authors： Kvien TK

更新日期：2004-01-01 00:00:00

abstract：:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the relief of the symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), sprains and strains, sports injuries and menstrual disorders, and have a small role in the management of patent ductus arteriosus in the neonate. In patients with RA, symptom...

journal_title：PharmacoEconomics

authors： Wynne HA,Campbell M

更新日期：1993-02-01 00:00:00

abstract：:Vaccination is an underutilised, low cost and effective method of preventing illness. Cost-effectiveness analysis discloses a beneficial role of influenza vaccination in preventing illness especially in patients over 65 years of age and in high risk patients. In one large study, when 150 million doses of influenza v...

journal_title：PharmacoEconomics

authors： Perez-Tirse J,Gross PA

更新日期：1992-09-01 00:00:00

abstract：OBJECTIVE:To evaluate the effect of using different cost-effectiveness measures in the economic evaluation of cholesterol-modifying pharmacotherapy. DESIGN AND SETTING:An economic model was used to examine the extent to which the relative cost effectiveness of cholesterol-modifying agents varies depending upon the cos...

journal_title：PharmacoEconomics

authors： Morris S,Godber E

更新日期：1999-08-01 00:00:00

abstract：:In today's environment, the demand for efficient healthcare resource allocation is increasing. As new technologies become available, allocation decisions become more complex and tools to assist decision makers in determining efficient allocations of healthcare resources are encouraged. Mathematical programs have multi...

journal_title：PharmacoEconomics

authors： Earnshaw SR,Dennett SL

更新日期：2003-01-01 00:00:00

abstract：OBJECTIVES:This study provides the results of a cost-effectiveness analysis of levetiracetam as an adjunctive treatment for refractory epilepsy from the Canadian Ministry of Health perspective. The main objective is to estimate the expected cost-effectiveness ratio expressed as the incremental cost per seizure-free day...

journal_title：PharmacoEconomics

authors： Blais L,Sheehy O,St-Hilaire JM,Bernier G,Godfroid P,LeLorier JJ

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:The use of granulocyte colony-stimulating factor (G-CSF) can enable dose intensification of chemotherapy in small-cell lung cancer (SCLC). However, given its acquisition cost, it is important to assess its cost effectiveness within a resource-constrained health service. OBJECTIVE:To assess the cost effectiv...

journal_title：PharmacoEconomics

authors： Bojke L,Sculpher M,Stephens R,Qian W,Thatcher N,Girling D

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVES:To obtain utility estimates suitable for use in economic models for chronic spontaneous (idiopathic) urticaria (CSU). METHODS:Patient-level data from three randomized clinical trials-ASTERIA I, ASTERIA II and GLACIAL-were analysed. Health states were derived from the Urticaria Activity Score over 7 days (UA...

journal_title：PharmacoEconomics

authors： Hawe E,McBride D,Balp MM,Tian H,Halliday A,Stull DE

更新日期：2016-05-01 00:00:00

abstract：:Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups of patients. Both direc...

journal_title：PharmacoEconomics

authors： Jønsson V,Hansen MM,Ljungman P,Kaasa S

更新日期：1999-02-01 00:00:00

abstract：:Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses...

journal_title：PharmacoEconomics

authors： Cohen BJ

更新日期：2003-01-01 00:00:00

abstract：:About half of the world's population live in Asia. Mandarin (the official language of China), Hindi and Japanese are among the ten languages spoken by the largest number of primary speakers. The numbers of Tamil and Malay speakers are expected to grow rapidly in the next few decades. Most health-related quality-of-lif...

journal_title：PharmacoEconomics

authors： Cheung YB,Thumboo J

更新日期：2006-01-01 00:00:00

abstract：:Cefotaxime is a parenterally administered third generation cephalosporin with a broad spectrum of antimicrobial activity. After more than a decade of use, cefotaxime continues to play an important role in the treatment of patients with serious infections, particularly those caused by Gram-negative bacteria. Clinical t...

journal_title：PharmacoEconomics

authors： Plosker GL,Foster RH,Benfield P

更新日期：1998-01-01 00:00:00

abstract：:As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of vedolizumab (Takeda UK) to submit evidence of the clinical effectiveness and cost effectiveness of vedolizumab for the treatment of patients with moderate-to-severe active ...

journal_title：PharmacoEconomics

authors： Essat M,Tappenden P,Ren S,Bessey A,Archer R,Wong R,Lobo A,Hoque S

更新日期：2016-03-01 00:00:00

abstract：OBJECTIVE:To evaluate the cost effectiveness of dabrafenib versus dacarbazine and vemurafenib as first-line treatments in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a Canadian healthcare system perspective. METHODS:A partitioned-survival analysis model with three mutually exclus...

journal_title：PharmacoEconomics

authors： Delea TE,Amdahl J,Wang A,Amonkar MM,Thabane M

更新日期：2015-04-01 00:00:00

abstract：BACKGROUND:Heart failure (HF) is a well-recognized public health concern and imposes high economic and societal costs. Decision analytic models exist for evaluating the economic ramifications associated with HF. Despite this, studies that appraise these modelling approaches for augmenting best-practice decisions remain...

journal_title：PharmacoEconomics

authors： Di Tanna GL,Bychenkova A,O'Neill F,Wirtz HS,Miller P,Ó Hartaigh B,Globe G

更新日期：2019-03-01 00:00:00

abstract：:Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and fu...

journal_title：PharmacoEconomics

authors： Campbell JD,Ramsey SD

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Pharmacogenetics offers the potential to improve health outcomes by identifying individuals who are at greater risk of harm from certain medicines. Routine adoption of pharmacogenetic tests requires evidence of their cost effectiveness. OBJECTIVE:The present review aims to systematically review published ec...

journal_title：PharmacoEconomics

authors： Plumpton CO,Roberts D,Pirmohamed M,Hughes DA

更新日期：2016-08-01 00:00:00

abstract：:Barrett's oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett's oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that ...

journal_title：PharmacoEconomics

authors： Arguedas MR,Eloubeidi MA

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:The symptoms of attention-deficit hyperactivity disorder (ADHD) are associated with impairment in multiple domains of health-related quality of life (HR-QOL). HR-QOL of children with ADHD has been assessed by relatively long multidimensional questionnaires. A review of the literature found no studies using t...

journal_title：PharmacoEconomics

authors： Matza LS,Secnik K,Mannix S,Sallee FR

更新日期：2005-01-01 00:00:00

abstract：:The objective of this study was to compare the cost effectiveness of amoxicillin/clavulanic acid with other antibacterial regimens for prophylaxis of infection after elective abdominal or gynaecological surgery. Data from 21 previously published comparative clinical trials were used to calculate statistical confidence...

journal_title：PharmacoEconomics

authors： Davey PG,Parker SE,Crombie IK,Jaderberg M

更新日期：1995-04-01 00:00:00

abstract：BACKGROUND:During the 1990s, a number of new cytotoxic agents with clinically relevant activity in non-small-cell lung cancer (NSCLC), and with a more favourable therapeutic index than drugs already in use, became available. Given the high prices of these new drugs and the large number of patients affected, it is impor...

journal_title：PharmacoEconomics

authors： Neymark N,Lianes P,Smit EF,van Meerbeeck JP

更新日期：2005-01-01 00:00:00

abstract：:The progressive disability of Parkinson's disease results in substantial burdens for patients, their families and society in terms of increased health resource use, poorer quality of life, caregiver burden, disrupted family relationships, decreases in social and leisure activities, deteriorating emotional well-being, ...

journal_title：PharmacoEconomics

authors： Rubenstein LM,DeLeo A,Chrischilles EA

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:Healthcare resource use data were collected for 1 year as part of the CAESAR (Canada, Australia, Europe, South Africa) clinical trial, which evaluated the effect of adding lamivudine to treatment regimens containing zidovudine in patients with HIV infection. This study showed that lamivudine-containing regim...

journal_title：PharmacoEconomics

authors： Lacey L,Mauskopf J,Lindrooth R,Pham S,Saag M,Sawyer W

更新日期：1999-01-01 00:00:00

abstract：:Epidural analgesia and intravenous analgesia with opioids are two techniques for providing pain relief for women in labour. Labour pain is comparable to surgical pain in its severity, and epidural analgesia provides better relief from this pain than intravenous analgesia; a meta-analysis quantified this improvement to...

journal_title：PharmacoEconomics

authors： Huang C,Macario A

更新日期：2002-01-01 00:00:00

abstract：:Cost-effectiveness analysis (CEA) is one of the main tools of economic evaluation. Every CEA is based on a number of assumptions, some of which may not be accurate, introducing uncertainty. Sensitivity analysis (SA) formalizes ways to measure and evaluate this uncertainty. Specific sources of uncertainty in CEA have b...

journal_title：PharmacoEconomics

authors： Jain R,Grabner M,Onukwugha E

更新日期：2011-04-01 00:00:00

abstract：:Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

journal_title：PharmacoEconomics

authors： Bermejo I,Tappenden P,Youn JH

更新日期：2017-11-01 00:00:00